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OBJECTIVES: To assess cost-effectiveness of rituximab (RTX) 1st line maintenance
treatment compared to observation (O) in patients with follicular lymphoma (FL)
from the Polish public payer perspective. METHODS: Efficacy and safety of ritux-
imab 1st line maintenance therapy was assessed based on the results of systematic
review and the PRIMA clinical trial. Direct medical costs were assessed based on
the data regarding clinical practice of FL treatment and medical resources use
gathered in 5 oncology centers. The following costs were calculated and included:
drugs, drug administration, treatment-related adverse events, lymphoma relapse
treatment, patient health monitoring. A life-time horizon (25 years) and public
payer perspective were assumed. Costs were discounted at 5% and effects at 3.5%.
A four health state Markov model (progression-free 1st line, progression-free sub-
sequent line, progression and death) was used. Sensitivity analysis was performed
testing the influence of various critical parameters such as utilities values, differ-
ent costs categories, length of time horizon and patient’s body surface. RESULTS:
Introduction of 1st line maintenance therapy with RTX resulted in gain of 1.4 life
years and 1.3 quality adjusted life years compared to observation. The total incre-
mental costs were 60,707 PLN (1 EURO3.96 PLN) which corresponded to an incre-
mental cost-effectiveness ratio (ICER) of 43,348 PLN and an incremental cost-utility
ratio (ICUR) of 47,357 PLN. Both values were below 110 000 PLN cost-effectiveness
threshold assumed by the Polish public payer. The results were sensitive to dis-
count rates, utilities values applied to the specific health states, length of time
horizon. None of the tested scenarios resulted in values of ICUR and ICER exceeding
the 110,000PLN threshold, providing evidence that rituximab treatment is cost-
effective from public payer perspective. CONCLUSIONS: Rituximab in 1st line
maintenance treatment of FL is an effective, safe and cost -effective therapeutic
option.
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TREATMENT OF METASTATIC COLORECTAL CANCER IN THE UK
Perard R1, Samyshkin Y2, Guillermin ALG3
1Merck Serono Limited, Feltham, UK, 2IMS Health, London, UK, 3IMS Health, London , UK
OBJECTIVES: To estimate the cost-effectiveness of cetuximab plus best supportive
care (BSC) or cetuximab plus chemotherapy in patients with EGFR-expressing
KRAS wild-type metastatic colorectal cancer who have failed at least two previous
chemotherapeutic regimens in the metastatic setting from the UK NHS
perspective. METHODS: A Markov model was developed to inform the cost-effec-
tiveness (CE) of cetuximab plus BSC and cetuximab plus chemotherapy both versus
BSC, and additionally the CE of cetuximab plus BSC and cetuximab plus chemo-
therapy both versus panitumumab plus BSC. Progression-free survival and overall
survival data were collected from the following clinical trials: Karapetis et al. 2008,
De Roock et al. 2007 and 2010, and Amado et al. 2008. These three clinical studies
were relevant to perform indirect treatment comparisons. RESULTS: In the base-
case analysis, treatments with cetuximab resulted in additional QALY as follows:
cetuximab plus BSC versus BSC (0.303), cetuximab plus chemotherapy versus BSC
(0.668), cetuximab plus BSC versus panitumumab plus BSC (0.193), and cetuximab
plus chemotherapy versus panitumumab plus BSC (0.616). The base-case incre-
mental cost effectiveness ratios (ICER) for cetuximab plus BSC and cetuximab plus
chemotherapy, both compared to BSC are in the region of £50,000 per QALY. Com-
pared to panitumumab plus BSC, the ICERs are below the NICE’s £30,000 willing-
ness-to-pay threshold. CONCLUSIONS:Weighting the QALYs gained with the NICE
supplementary advice, suggests that cetuximab plus BSC or cetuximab plus che-
motherapy is potentially a cost-effective use of NHS resources in this setting.
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OBJECTIVES: To assess the cost-effectiveness in France of current G-CSF strategies
as PP (from first cycle and before an FN event) and SP (after an FN event) for NHL
patients receiving cytotoxic chemotherapy. METHODS: A Markov model was de-
veloped to calculate cost per FN events avoided, life-year saved (LYS), and quality
adjusted life year (QALY); results were expressed as incremental cost-effectiveness
ratios (ICERs). ICERs for 9 prophylaxis strategies were evaluated for three NHL
chemotherapies (CHOP, CHOP-R and ACVBP): PP or SP with pegfilgrastim (Neu-
lasta®), 6-day filgrastim (Neupogen®), 11-day filgrastim, 6-day lenograstim; and no
prophylaxis. All strategies were compared to no prophylaxis. FN-related outcomes
including FN-hospitalizations, FN-mortality and RDI were assessed using epidemi-
ologic data, utility and chemotherapy-related FN-risk (21% for CHOP-21, 19% for
RCHOP-21, 52% for ACVBP). Direct healthcare costs (G-CSF, administration, and
FN-related events) were calculated from French Health insurance perspective.
Costs and outcomes were discounted (4%/year). Based on international guidelines,
PP should be given to high-risk patients (FN risk320%). RESULTS: In the high che-
motherapy FN-risk population, pegfilgrastim was the most cost-effective G-CSF
compared to SP-pegfilgratim. For instance, in patients undergoing ACVBP chemo-
therapy, ICERs with PP-pegfilgrastim were €2,019 per FN avoided, €10,194 per QALY
gained and €8,632 per LYS versus SP-pegfilgrastim. In RCHOP-21 and without con-
sidering patient risk factors, if SP was considered instead of no prophylaxis, peg-
filgrastim was the dominant G-CSF with ICERs of €2,112 per FN avoided, €14,703 per
QALY gained and €11,940 per LYS versus no prophylaxis. CONCLUSIONS: With
French settings, pegfilgrastim is the most cost-effective PP-G-CSF in high chemo-
therapy FN-risk patients versus SP-pegfilgrastim. After an FN event, pegfilgrastim
is the most cost-effective SP-G-CSF versus no prophylaxis.
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OBJECTIVES: To assess the public health impact of the quadrivalent (6,11,16,18)
HPV vaccination program for São Paulo, Brazil.METHODS:A published mathemat-
ical model of the transmission dynamics of HPV infection and disease was adapted
for São Paulo, Brazil. The model captured direct protective effects of vaccination
and indirect effects (herd immunity). Model inputs were used from Brazil or the
Latin/America region when available; otherwise, the default values in the original
model were used. Maintaining current cervical cancer screening practices in Brazil,
we evaluated two strategies: routine vaccination of females by age 12 (S1), and S1
combined with a temporary (5 years) female catch-up program for age 12–24 years
(S2). The vaccine coverage rates were 85% for the routine and 95% by age 26 years
for the catch-up vaccination programs. RESULTS: Comparing S1 to no vaccination,
we estimated the cumulative percent (absolute cases) reduction in HPV 6/11/16/18-
related incident genital warts-female, genital warts-male, cervical intraepithelial
neoplasia (CIN) grade 1, CIN 2/3, cervical cancer cases, and cervical cancer deaths
would be 78% (2,488,240), 67% (2,166,770), 68% (360,235), 65% (1,154,566), 47%
(135,810), and 44% (39,147), respectively, over 100 years. Compared to S1, S2 pro-
vided additional cumulative percent (absolute cases) reduction of 9% (273,866), 11%
(357,728), 7% (39,455), 7% (131,861), 7% (19,620), and 7% (6,009) in HPV 6/11/16/18-
related incident genital warts-female, genital warts-male, CIN 1, CIN 2/3, cervical
cancer cases, cervical cancer deaths. CONCLUSIONS: A prophylactic quadrivalent
HPV vaccination program for females in Sao Paulo, Brazil can substantially reduce
the incidence of cervical cancer, CIN, and genital warts. Female catch up vaccina-
tion may provide greater reductions in HPV-related diseases.
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OBJECTIVES: Evaluate the cost-effectiveness analysis of erlotinib compared with
docetaxel and pemetrexed in the second-line treatment of advanced non-small-
cell-lung cancer (NSCLC) from a societal perspective in a Russian setting.
METHODS: A Markov state transition model, based on two randomized phase III
studies of erlotinib versus pemetrexed (HORTC) and pemetrexed versus docetaxel
(Nasse H. et al 2005), was used to estimate total direct costs and quality-adjusted
life years (QALYs). Data about cost of medical services and drugs are received from
the price-list of out-patient medical aid in clinic MMA of I.M.Sechenov 01.02.2011,
site minzdravsoc.ru//medicine and other accessible electronic resources. Costs,
effectivenesses, utilities were discounted at 3%. Sensitivity analysis for key param-
eters in the model was conducted. RESULTS: Erlotinib was associated with a re-
duction in total costs (1 179 452 roubles versus 1 260 607 roubles and 1 769 367
roubles) and improved outcomes (total QALYs of 0.299 versus 0.248 and 0.271) in
comparison with docetaxel and pemetrexed, respectively. Sensitivity analysis
showed that major factors influencing cost-effectiveness and cost-utility ratios are
survival gain, price of drugs, discount rates. CONCLUSIONS: In summary erlotinib
is more cost-effective in comparison with docetaxel and pemetrexed for second-
line treatment of advanced NSCLC due to lower adverse event and drug adminis-
tration costs.
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OBJECTIVES: This study is devoted on a comparative pharmacoeconomic analysis
regimes XELOX  BV (bevacizumab) versus XELOX  CET (cetuximab) treatment
(q3w); FOLFOX4  BV and FOLFOX4  CET (q2w) in the treatment of mCRC. The
efficacy and safety of combined treatment regimens based on the data of interna-
tional clinical trials. METHODS: Medical services were taken from the standards of
medical care for patients with ÑRC and their costs were based on the price-list of
Cancer Research Center. The cost analysis of anticancer and related drugs were
based on the information about limit selling/import prices of vital and essential
drugs. The main characteristics for Markov’s model were: the Markov states (with-
out progression, progression, death); a Markov’s cycle (1 month); the time horizon
(5 years). RESULTS: The cost of diagnosis was 16757 rubles, the medical services –
222802 rubles. The mCRC therapy as a first line by XELOX in combination with BV
was 1029694 rubles or with CET–1899867 ruble; FOLFOX4 in combination with BV–
1109402 rubles or with CET–2026917 rubles. The highest CER was for mode
XELOXCET-263870 rubles. The Markov’s model shows that the COST/QALY and
COST/LYG will above with each year, but in comparing groups with BV or CET
therapy in the next 5 years, it was shown a tendency of the increase in cost per
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QALY and per LYG for XELOX/FOLFOX4CET. CONCLUSIONS: As a result of cost
analysis it was identified anticancer schemes, requiring the lowest and highest
costs. The account of CER, Markov’s model construction have demonstrated the
benefits of using XELOX/FOLFOX4BV regimes in patients with mCRC.
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OBJECTIVES: To perform a cost-effectiveness analysis comparing nanoparticle al-
bumin bound (nab) paclitaxel (N-P, 260 mg/m2) with solvent-based paclitaxel (S-P,
175 mg/m2) given every 3 weeks as second-line treatment for metastatic breast
cancer (MBC) from the perspective of the Portuguese National Health System
(PNHS). METHODS: A Markov type stochastic process including disease states pro-
gression-free, progressive disease and death was designed to model long-term
effectiveness and costs. Patient level data from a randomized, open-label, phase III
study (n460) was used to estimate parametric survival models (weibull) for time
to treatment discontinuation, time to progression and time to death. Effectiveness
was measured in life years (LY). Only direct costs were considered (drugs, medical
visits, hospitalization, adverse events (grade 3/4) treatment and monitoring, termi-
nal care). The source for unit costs was the PNHS price list. Time horizon was fixed
at 4 years. Probabilistic sensitivity analysis was conducted with Monte Carlo sim-
ulations. Discount rates of 5%/year were applied to costs and effectiveness.
RESULTS: A mean gain of 25 LY (95%CI: [2; 46]) was estimated for each 100 patients
treated with N-P. This would represent an average 22% life expectancy increment.
The estimated mean incremental cost of N-P treated patients was 7370 € (95%CI:
[6762; 7945]). Corresponding average incremental cost-effectiveness ratio was
29,535€/LY. Probabilistic sensitivity analysis revealed an 83% probability of N-P to
be cost-effective in comparison with S-P, at the commonly accepted threshold of
50,000€. CONCLUSIONS: nab-Paclitaxel may be considered a cost-effective drug as
it adds a substantial relative increment in the overall survival over second-line
solvent -based paclitaxel monotherapy in women with metastatic breast cancer.
The estimation of long-term benefits of nab-Paclitaxel beyond the clinical trial
follow-up period by Markov based modelling can provide valuable support to de-
cision making in the context of scarce resources.
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OBJECTIVES: Over the past decades, research focusing on new chemotherapeutic
agents for patients with inoperable NSCLC have reported only modest gains in
survival. These health gains are achieved at considerable costs, but economic ev-
idence on superiority of one of the agents in terms of cost-effectiveness is lacking.
The objective of this systematic review is to assess fully published cost-effective-
ness studies comparing the new agents docetaxel, paclitaxel, vinorelbine, gemcit-
abine and pemetrexed, and the targeted therapies erlotinib and gefitinib among
each other. METHODS: PubMed, EMBASE.com and Economic Evaluations (via the
Cochrane Library, Wiley) were systematically searched for fully published studies
from the past 10 years. Studies were screened by two independent reviewers ac-
cording to a priori inclusion criteria. The methodological quality of the included
studies was evaluated by two independent reviewers using standardized assess-
ment tools. RESULTS: A total of 222 potential studies were identified. Eleven cost-
effectiveness or cost-utility studies were included. The methodological quality of
the full economic evaluations was fairly good. Transparency in costs and resource
use, details on statistical tests and sensitivity analysis were points for improve-
ment. In first-line treatment, one study indicated that gemcitabine-cisplatin was
cost-effective compared to paclitaxel-based regimens, and another study indicated
that gemcitabine-cisplatin was cost-effective compared to platinum-based regi-
mens containing either paclitaxel, vinorelbine or docetaxel in terms of progres-
sion-free survival. In a third study, pemetrexed-cisplatin was cost-effective com-
pared to gemcitabine-cisplatin in patients with nonsquamous cell carcinoma. In
second-line treatment, docetaxel was cost-effective compared to BSC (range of
ICERs per LYG: US$22,190-US$32,133). Erlotinib was cost-effective compared to pla-
cebo in one study (ICER per LYG: US$33,728). Docetaxel and pemetrexed were dom-
inated by erlotinib in one study and in two studies, respectively. CONCLUSIONS:
We found indications for superiority in terms of cost-effectiveness of gemcitabine-
cisplatin in a first-line setting and for erlotinib in second-line setting.
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OBJECTIVES: To evaluate whether the use of bevacizumab  paclitaxel offers best
cost-effective results regarding the use of paclitaxel for patients with metastatic
breast cancer mBC METHODS: The treatment was evaluated up to the progression
of the disease, rescue management and palliative up to to death in a Markov model,
operating 65 cycles of 28 days. An incremental cost effectiveness analysis and
sensitivity analysis was performed considering as an outcome measure progres-
sion-free survival (PFS), on the cohort of 2000 patients with Her2 Ne mBC negative
and a subanalysis of the populations of patients with triple negative of patients
with Her2 Neu Negative, taking into account direct medical costs and social costs
due to premature death, in a horizon of 5 years (discount rate 5%). RESULTS: The
40.35% of patients survived after 12 months using bevacizumab paclitaxel, while
only 35.20% did so with only administered paclitaxel. 59.6% of these patients were
PFS with combination therapy, while 37.71% did with monotherapy. Combined
therapy provides more effectiveness than monotherapy in terms of overall sur-
vival, progression-free survival (PFS) and therapeutic response The incremental
cost of bevacizumab  paclitaxel is $7529 USD obeying the PFS difference in time
between the two cohorts, and higher consumption on the combination versus
monotherapy. For triple negative subpopulation, the ICER is $1793 USD while for
the sub-population of HER 2 is $1448 USD. The ICER is compared against a threshold
of 3 times GDP per capita in Mexico. The ICER is lower than the threshold, so it is
cost-effective CONCLUSIONS: The combination of bevacizumab  paclitaxel, for
all cases studied, represents a better alternative cost effective versus paclitaxel
monotherapy.
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OBJECTIVES: Chemotherapy induced nausea and vomiting (CINV) is a common
and distressing adverse effect of cancer chemotherapy. Despite the widespread use
of prophylactic anti-emetic agents, control of CINV induced by moderately emeto-
genic chemotherapy (MEC) remains sub-optimal, with breast cancer patients rep-
resenting a sub-population at increased risk. The aim of this analysis was to eval-
uate the cost-effectiveness of an aprepitant regimen compared to current clinical
practice in Scotland for the prevention of CINV in breast cancer patients receiving
MEC. METHODS: A decision-analytic model was developed to estimate the costs
and health outcomes associated with the prevention of CINV over a single chemo-
therapy cycle with a time horizon of 5 days post-chemotherapy. The analysis com-
pared an aprepitant regimen (aprepitant, ondansetron and dexamethasone pre-
chemotherapy, and aprepitant for 2 days following chemotherapy) to a commonly
used regimen in Scottish clinical practice (dexamethasone and ondansetron pre-
chemotherapy, and dexamethasone and domperidone for 2 days following chemo-
therapy). The health outcomes in the model were: complete protection (no emesis,
no rescue therapy and maximum nausea 25mm on VAS); complete response (no
emesis and no rescue therapy, but maximum nausea 25 mm); incomplete re-
sponse (some emesis or rescue therapy). Transition probabilities were based on a
randomised clinical trial comparing aprepitant and standard of care regimens,
which included 438 breast cancer patients. Chemotherapy among breast cancer
patients was comprised of anthracycline plus cyclophosphamide (AC) regimens
(87.2%) and non-AC regimens (12.8%). RESULTS:An aprepitant regimen when com-
pared to Scottish clinical practice for preventing CINV in breast cancer patients
receiving MEC is cost-effective with an incremental cost effectiveness ratio (ICER)
of £14,610 per QALY. CONCLUSIONS: Aprepitant is a cost-effective option for the
prevention of acute and delayed nausea and vomiting induced by MEC for the
treatment of breast cancer in Scottish clinical practice.
PCN96
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OBJECTIVES: The adjuvant chemotherapy for stage III Colon Cancer is based in
oxaliplatin for 6 months. FOLFOX-4, FLOX and XELOX were very similar results in
efficacy and safety. There are some differences in total doses and form of the
application. We present the differences in direct and indirect costs of the 3
schemes in the National Cancer Institute (NCI) of Mexico. METHODS: We analyzed
130 patients with stage III Colon Cancer treated in the NCI of Mexico, from January
2004 to August 2010. The body surface mean was 1.62 and the costs were calculated
based on current prices-government in November 2010. We considered the follow-
ing costs: 1) Chemotherapy / BS , 2) Prophylactic anti-emetics, 3) Use of central
catheter (patients with XELOX, not used catheter), 4) Medical offices, 5) Laboratory
tests, 6) Adverse events grade 3-4 (used the frequency of reports of Andre T 2004/
FOLFOX, Kuebrer JP 2007/FLOX and Schomll HJ 2007/XELOX) and 7) Number of visits
to the Hospital and indirect costs at each visit (cost for visit was $ 39.68 US). All costs
was report in US dollars ($ 12.50 Mexican pesos  1 dollar US) RESULTS: The
estimated costs incurred by adjuvant chemotherapy regimen are reported as fol-
lows (FLOX, FOLFOX-4, XELOX): Chemotherapy ($13,349, $13,685, $15,365), Anti-
emetics ($326, $433, $288), Subclavian catéter-maintenance ($237, $237, $0), QT –
application ($764 $1,433, $352), Blood tests ($422, $563, $376), Medical offices ($405,
$527, $365), Adverse events grade 3-4 ($726, $568, $371), Hospital visits (number)
(40, 61, 17). Indirects costs for visit $1,587, $2,420, $675). The total cost of the treat-
ment is ($17,817, $19,866, $ 17,790). CONCLUSIONS: The FOLFOX scheme was more
expensive with the highest number of hospital visits. The scheme XELOX is more
practice, less expensive, less visit at the hospital and with less impact on lifestyle.
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